KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $431.9 million.

  • Royalty Pharma's Shares Outstanding (Weighted Average) fell 382.96% to $431.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $431.9 million, marking a year-over-year decrease of 382.96%. This contributed to the annual value of $448.2 million for FY2024, which is 13.05% up from last year.
  • Per Royalty Pharma's latest filing, its Shares Outstanding (Weighted Average) stood at $431.9 million for Q3 2025, which was down 382.96% from $429.5 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Shares Outstanding (Weighted Average) peaked at $451.0 million during Q2 2024, and registered a low of $389.8 million during Q1 2021.
  • For the 5-year period, Royalty Pharma's Shares Outstanding (Weighted Average) averaged around $435.6 million, with its median value being $438.0 million (2022).
  • Per our database at Business Quant, Royalty Pharma's Shares Outstanding (Weighted Average) soared by 1573.82% in 2021 and then plummeted by 477.94% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Shares Outstanding (Weighted Average) stood at $414.8 million in 2021, then grew by 5.59% to $438.0 million in 2022, then rose by 2.2% to $447.6 million in 2023, then increased by 0.13% to $448.2 million in 2024, then dropped by 3.64% to $431.9 million in 2025.
  • Its last three reported values are $431.9 million in Q3 2025, $429.5 million for Q2 2025, and $435.5 million during Q1 2025.